Skip to main content

Table 2 Fibromyalgia Impact Questionnaire scores throughout the study period

From: Trazodone for the treatment of fibromyalgia: an open-label, 12-week study

  baseline week 6 week 12 P (anova)  
Total score (mean ± s.d.) 77.5 ± 13.4 70.8 ± 15.8*** 67.9 ± 17.9*** < 0.0001  
ES   0.5 0.72   
Work (mean ± s.d.) 8.15 ± 1.6 7.42 ± 2.0** 7.43 ± 2.1** = 0.0014  
ES   0.46 0.45   
Pain (mean ± s.d.) 8.26 ± 1.7 7.78 ± 1.7* 7.46 ± 1.9*** = 0.0007  
ES   0.28 0.47   
Fatigue (mean ± s.d.) 8.75 ± 1.4 8.09 ± 2.1* 8.03 ± 2.1* = 0.0140  
ES   0.47 0.51   
Morning tiredness (mean ± s.d.) 8.86 ± 1.4 7.78 ± 2.4** 7.72 ± 2.6** = 0.0005  
ES   0.77 0.81   
Stiffness (mean ± s.d.) 8.04 ± 2.0 7.12 ± 2.8** 6.94 ± 2.8*** = 0.0006  
ES   0.46 0.55   
Anxiety (mean ± s.d.) 8.15 ± 1.9 7.44 ± 2.7* 7.04 ± 2.7*** = 0.0010  
ES   0.37 0.58   
Depression (mean ± s.d.) 7.94 ± 2.5 6.98 ± 2.9 7.06 ± 3.0 = 0.0027  
ES   0.38 0.35   
  1. *: p < 0.05, **:p < 0.01, and ***:p < 0.001 in relation to baseline (Dunnett's post-test)
  2. ES: effect size;bold: moderate and large effect sizes